JOMPAC
Journal of Medicine and Palliative Care

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

eISSN: 2717-7505
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Prognostic factors for survival in pancreatic cancer patients received radiotherapy: a single-center experience
Abstract
Aims: To investigate survival outcomes and factors affecting the prognosis of patients with pancreatic cancer (PC) who received radiotherapy (RT). Material and
Methods: A total of 73 patients with PC who received RT between 2013 and 2021 were included in the study. Clinical, demographic, and histopathological features of the patients, and the goal of RT (adjuvant, definitive, neoadjuvant, or palliative) were recorded.
Results: Median age of the patients was 62 (37-78). Male to female ratio was 1.6. In patients treated with adjuvant (n=52), definitive (n=13), and palliative (n=7) RT, median overall survival (OS) was 25.7 (11.6-39.7), 16 (7-67), and 9 (5-52) months, respectively. Survival time of 1 patient who received neoadjuvant RT was 26.6 months. Lymph node ratio (LNR) was significantly associated with OS. Patients with LNR ?0.4 had better survival compared to those with LNR >0.4 (p=0.003). Furthermore, patients with LNR ?0.4 and received adjuvant RT survived longer than the rest of the patients (12.1 vs. 7.7 months, p=0.001). Larger tumors (p=0.04) and LNR (p=0.003) were associated with poorer survival in univariate analysis, however, in the multivariate analysis, OS was found significantly affected only by LNR (p=0.01). Other factors were not found associated with survival.
Conclusion: LNR had a strong correlation with OS in PC patients treated with radiation. Smaller LNR was associated with better survival in patients who received RT in the adjuvant setting.

Keywords : Pancreatic cancer, prognostic factors, survival, radiotherapy

Download Article


1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021.CA Cancer J Clin 2021; 71: 7-33.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M.Pancreatic cancer. Lancet 2011; 378: 607-20.
3. Heinen MM, Verhage BA, Goldbohm RA, van den Brandt PA.Active and passive smoking and the risk of pancreatic cancer inthe Netherlands Cohort Study. Cancer Epidemiol BiomarkersPrev 2010; 19: 1612-22.
4. Eijgenraam P, Heinen MM, Verhage BA, Keulemans YC,Schouten LJ, van den Brandt PA. Diabetes type II, other medicalconditions and pancreatic cancer risk: a prospective study in TheNetherlands. Br J Cancer 2013; 109: 2924-32.
5. Fitzpatrick SG, Katz J. The association between periodontaldisease and cancer: a review of the literature. J Dent 2010; 38: 83-95.
6. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology ofpancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol2009; 6: 699-708.
7. Lucenteforte E, La Vecchia C, Silverman D, et al. Alcoholconsumption and pancreatic cancer: a pooled analysis in theInternational Pancreatic Cancer Case-Control Consortium(PanC4). Ann Oncol 2012; 23: 374-82.
8. Govindarajan A, Tan JC, Baxter NN, Coburn NG, Law CH.Variations in surgical treatment and outcomes of patients withpancreatic cancer: a population-based study. Ann Surg Oncol2008; 15: 175-85.
9. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatmentand outcome of pancreatic cancer in the United States. Ann SurgOncol 2007; 14: 1320-6.
10. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy withgemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlledtrial. JAMA 2007; 297: 267-77.
11. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, PistersPW. Combined modality treatment of resectable and borderlineresectable pancreas cancer: expert consensus statement. AnnSurg Oncol 2009; 16: 1751-6.
12. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomywith or without distal gastrectomy and extended retroperitoneallymphadenectomy for periampullary adenocarcinoma, part 2:randomized controlled trial evaluating survival, morbidity, andmortality. Ann Surg 2002; 236: 355-66.
13. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomyfor pancreatic adenocarcinoma: postoperative adjuvantchemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-33.
14. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevanceof lymph node ratio following pancreaticoduodenectomy forpancreatic cancer. Surgery 2007; 141: 610-8.
15. Pantalone D, Ragionieri I, Nesi G. Improved survival in smallpancreatic cancer. Dig Surg 2001; 18: 41-6.
16. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapyand 5-fluorouracil after curative resection of cancer of thepancreas and periampullary region: phase III trial of the EORTCgastrointestinal tract cancer cooperative group. Ann Surg 1999;230: 776-82.
17. Hsu CC, Herman JM, Corsini MM, et al. Adjuvantchemoradiation for pancreatic adenocarcinoma: the JohnsHopkins Hospital-Mayo Clinic collaborative study. Ann SurgOncol 2010; 17: 981-90.
18. Herman JM, Swartz MJ, Hsu CC, et al. Analysis offluorouracil-based adjuvant chemotherapy and radiation afterpancreaticoduodenectomy for ductal adenocarcinoma of thepancreas: results of a large, prospectively collected database at theJohns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-10.
19. Corsini MM, Miller RC, Haddock MG, et al. Adjuvantradiotherapy and chemotherapy for pancreatic carcinoma: theMayo Clinic experience (1975-2005). J Clin Oncol 2008; 26:3511-6.
20. Versteijne E, Suker M, Groothuis K, et al. PreoperativeChemoradiotherapy Versus Immediate Surgery for Resectableand Borderline Resectable Pancreatic Cancer: Results of theDutch Randomized Phase III PREOPANC Trial. J Clin Oncol2020; 38: 1763-73.
21. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapyafter disease control with chemotherapy in locally advancedpancreatic adenocarcinoma in GERCOR phase II and III studies.J Clin Oncol 2007; 25: 326-31.
22. Shinchi H, Takao S, Noma H, et al. Length and quality of survivalafter external-beam radiotherapy with concurrent continuous5-fluorouracil infusion for locally unresectable pancreatic cancer.Int J Radiat Oncol Biol Phys 2002; 53: 146-50.
23. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapytreatment of locally advanced pancreatic cancer: gemcitabineversus 5-fluorouracil, a randomized controlled study. Int J RadiatOncol Biol Phys 2003; 57: 98-104.
24. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancerstatistics, trends, and multiple primary cancer analyses from theSurveillance, Epidemiology, and End Results (SEER) Program.Oncologist 2007; 12: 20-37.
25. Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen19-9 in pancreatic cancer: a meta-analysis. Tumour Biol 2014; 35:7459-65.
26. Chang DK, Johns AL, Merrett ND, et al. Margin clearance andoutcome in resected pancreatic cancer. J Clin Oncol 2009; 27:2855-62.
27. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW.Curative resection is the single most important factor determiningoutcome in patients with pancreatic adenocarcinoma. Br J Surg2004; 91: 586-94.
28. Herman JM, Moreno AC, Crane CH, Iacobuzio-Donahue CA,Abrams RA. Pancreatic Cancer. In: Joel ET, Robert LF, Jeff MM,editors. Gunderson & Tepper's Clinical Radiation Oncology. 5thed. Philadelphia: Elsevier; 2021. p. 946-72.
29. Asiyanbola B, Gleisner A, Herman JM, et al. Determining patternof recurrence following pancreaticoduodenectomy and adjuvant5-flurouracil-based chemoradiation therapy: effect of numberof metastatic lymph nodes and lymph node ratio. J GastrointestSurg 2009; 13: 752-9.
30. Pongprasobchai S, Pannala R, Smyrk TC, et al. Long-termsurvival and prognostic indicators in small (<or=2 cm) pancreaticcancer. Pancreatology 2008; 8: 587-92.
Article available in :
Volume 4, Issue 1, 2023
Page : 58-62
https://doi.org/10.47582/jompac.1200674
Article Information
Submitted : 07 Kas 2022
Accepted : 31 Oca 2023
Corresponding Author :

Hilal Alkış: Department of Radiation Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey

[email protected]
Citation : Alkış H. Prognostic factors for survival in pancreatic cancer patients received radiotherapy: a single-center experience. J Med Palliat Care 2023; 4(1): 58-62.

Read: 45
Cited: 0
Download : 43
_Footer